Drug Trial Radar · NCT00182312
Caffeine for Apnea of Prematurity (CAP)
Last checked: Nov 20, 2026Latest source record: Mar 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Planned (sponsor's estimate)
Start
Oct 1999
Primary completion
Mar 2007
Study completion Jul 2016
Sponsor
- Lead sponsor
- McMaster UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); National Health and Medical Research Council, Australia
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, up to 10 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250 grams at birth. Approximately 30-40% of these high-risk infants either die or survive with lasting disabilities. The aim of this research is to reduce this heavy burden of illness. A multi-center randomized controlled trial has been designed in which 2000 very low birth weight infants will be enrolled. Our goal is to determine whether the avoidance of methylxanthine drugs will improve survival without disability to 18 months, corrected for prematurity. Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and breath-holding spells in premature infants. However, there is a striking lack of evidence for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally occurring substance, called adenosine, which protects the brain during episodes of oxygen deficiency. Such episodes are common in infants who are treated with methylxanthines. It is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore, this trial will clarify whether methylxanthines cause more good than harm in very low birth weight infants.
Conditions
- Apnea of Prematurity
Interventions
Caffeine citrate injectionDrug
Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection. Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established. Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- combined rate of mortality and neurodevelopmental disability in survivors at a corrected age of 18 months.Time frame: corrected age of 18 months
Locations
34 sites in 9 countries. Site status is shown where the registry gives one.
Brooklyn Hospital Center
Brooklyn, New York
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Women's & Children's Hospital
Adelaide, South Australia, Australia
Mercy Hospital for Women
Melbourne, Victoria, Australia
Royal Women's Hospital
Melbourne, Victoria, Australia
Centre Hospitalier Universitaire de Quebec
Québec, Canada
Foothills Hospital
Calgary, Alberta, Canada
Children's & Women's Health Centre of BC
Vancouver, British Columbia, Canada
Victoria General Hospital
Victoria, British Columbia, Canada
St. Boniface General Hospital
Winnipeg, Manitoba, Canada
Moncton Hospital
Moncton, New Brunswick, Canada
McMaster University
Hamilton, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
Ottawa Hospital
Ottawa, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
Sunnybrook & Women's College Health Science Centre
Toronto, Ontario, Canada
Windsor Regional Hospital
Windsor, Ontario, Canada
Royal Victoria Hospital
Montreal, Quebec, Canada
University of Sherbrooke
Sherbrooke, Quebec, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Ludwig Maximilian University
Munich, Germany
University of Tuebingen
Tübingen, Germany
Soroka University Medical Center
Beersheba, Israel
Meir General Hospital
Kfar Saba, Israel
Kaplan Medical Center
Rehovot, Israel
Academisch Medisch Centrum
Amsterdam, Netherlands
University Hospital Maastricht
Maastricht, Netherlands
Astrid Lindgren's Children's Hospital
Stockholm, Sweden
University Children's Hospital Basel
Basel, Switzerland
University Hospitals of Geneve
Geneva, Switzerland
University of Zurich
Zurich, Switzerland
South Cleveland Hospital
Middlesbrough, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Royal Maternity Hospital
Belfast, Northern Ireland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.